SIGA Siga Technologies (SIGA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001010086
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
97
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · no price filed
Siga Technologies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for SIGA TECHNOLOGIES INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 29.7% of the 100,875 shares held after it.
- No other insider sold within 30 days.
- 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Antal James sold about $234.6K of SIGA on Dec 9, 2021, the largest insider sale at the company on our record; 97 funds added in the latest 13F quarter.1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
97 funds bought in last quarter
more than 67% of Pharma & Biotech
Revenue
-31.8% year over year
below 73% of Pharma & Biotech
Margin
24.6% net margin
more than 88% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
8.7% of the float short (float per yahoo 2026-10-27) · 6.4 days to cover · settled 2026-10-15
more than 51% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SIGA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-57.5%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SIGA: institutional holders (13F)
13F holdings, latest reported quarter
4,186,282 sh
$15.2M
2,719,568 sh
$9.9M
2,327,144 sh
$8.5M
1,712,701 sh
$6.2M
1,506,065 sh
$5.5M
Congress trades in SIGA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SIGA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SIGA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Acquirers Small and Micro Deep Value ETF
$219.4K position · as of 2026-05-31
0.8%
Cambria Micro and SmallCap Shareholder Yield ETF
$256.4K position · as of 2026-07-31
0.8%
Invesco NASDAQ Future Gen 200 ETF
$62.8K position · as of 2026-05-31
0.3%
iShares US Small Cap Value Factor ETF
$602.7K position · as of 2026-06-30
0.3%
Royce Small-Cap Value Fund
$275.6K position · as of 2026-06-30
0.2%
Royce Capital Fund - Small-Cap Portfolio
$446.7K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
2
Phase 2
1 active
2
Phase 3
0 active
2
Phase 4
0 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF · 2018-09-10
$626.5M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Dr. Gomez.
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$1.8M
$1.8M
$1.4M
+57%
+15%
2022
$1.7M
$1.7M
$993.9K
+76%
+11%
2021
$1.7M
$1.7M
$1.3M
+58%
+25%
2020
$1.6M
$1.6M
$1.3M
+52%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 97 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SIGA financials
Revenue growth
-31.8%
XBRL, annual
Net margin
24.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$53.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SIGA
| FY Dec 2025 | $94.6M |
| FY Dec 2024 | $138.7M |
| FY Dec 2023 | $139.9M |
| FY Dec 2022 | $110.8M |
| FY Dec 2021 | $133.7M |
| Jun 2026 | $41.0M |
| Mar 2026 | $6.2M |
| Dec 2025 | $3.8M |
| Sep 2025 | $2.6M |
| Jun 2025 | $81.1M |
| Mar 2025 | $7.0M |
| Dec 2024 | $81.5M |
| Sep 2024 | $10.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-5.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SIGA
| FY Dec 2025 | +24.6% |
| FY Dec 2024 | +42.7% |
| FY Dec 2023 | +48.6% |
| FY Dec 2022 | +30.6% |
| FY Dec 2021 | +52.0% |
| Jun 2026 | +30.4% |
| Mar 2026 | -55.3% |
| Dec 2025 | -143.1% |
| Sep 2025 | -243.0% |
| Jun 2025 | +43.7% |
| Mar 2025 | -5.8% |
| Dec 2024 | +56.2% |
| Sep 2024 | +13.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$20.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SIGA
| FY Dec 2025 | $43.1M |
| FY Dec 2024 | $48.7M |
| FY Dec 2023 | $94.8M |
| FY Dec 2022 | $41.6M |
| FY Dec 2021 | $11.4M |
| Jun 2026 | $15.2M |
| Mar 2026 | -$8.7M |
| Dec 2025 | -$16.9M |
| Sep 2025 | -$10.1M |
| Jun 2025 | $63.1M |
| Mar 2025 | $7.0M |
| Dec 2024 | $56.3M |
| Sep 2024 | -$7.4M |
At each fiscal year end
Single quarter
Debt to equity
0.48x
long-term 2019-09-30 (82 months older than the period end) plus current 2020-12-31 (66 months older than the period end); equity 2026-06-30
Debt to equity SIGA
| FY Dec 2025 | 0.40x |
| FY Dec 2024 | 0.37x |
| FY Dec 2023 | 0.40x |
| FY Dec 2022 | 0.46x |
| FY Dec 2021 | 0.45x |
| Jun 2026 | 0.48x |
| Mar 2026 | 0.52x |
| Dec 2025 | 0.40x |
| Sep 2025 | 0.39x |
| Jun 2025 | 0.38x |
| Mar 2025 | 0.37x |
| Dec 2024 | 0.37x |
| Sep 2024 | 0.47x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.26x
TTM operating cash flow over long-term 2019-09-30 (82 months older than the period end) plus current 2020-12-31 (66 months older than the period end)
Cash flow to debt SIGA
| FY Dec 2025 | 0.55x |
| FY Dec 2024 | 0.62x |
| FY Dec 2023 | 1.20x |
| FY Dec 2022 | 0.53x |
| FY Dec 2021 | 0.15x |
| Jun 2026 | -0.26x |
| Mar 2026 | 0.35x |
| Dec 2025 | 0.55x |
| Sep 2025 | 1.48x |
| Jun 2025 | 1.51x |
| Mar 2025 | 0.78x |
| Dec 2024 | 0.62x |
| Sep 2024 | 0.91x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-1.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SIGA
| FY Dec 2025 | +11.2% |
| FY Dec 2024 | +28.7% |
| FY Dec 2023 | +37.1% |
| FY Dec 2022 | +19.7% |
| FY Dec 2021 | +45.7% |
| Jun 2026 | -1.5% |
| Mar 2026 | +11.0% |
| Dec 2025 | +11.2% |
| Sep 2025 | +39.9% |
| Jun 2025 | +43.6% |
| Mar 2025 | +25.5% |
| Dec 2024 | +28.7% |
| Sep 2024 | +58.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-1.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SIGA
| FY Dec 2025 | +10.0% |
| FY Dec 2024 | +23.7% |
| FY Dec 2023 | +30.3% |
| FY Dec 2022 | +16.5% |
| FY Dec 2021 | +38.1% |
| Jun 2026 | -1.4% |
| Mar 2026 | +8.7% |
| Dec 2025 | +10.0% |
| Sep 2025 | +34.9% |
| Jun 2025 | +38.4% |
| Mar 2025 | +19.8% |
| Dec 2024 | +23.7% |
| Sep 2024 | +48.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SIGA
| FY Dec 2025 | +13.9% |
| FY Dec 2024 | +41.1% |
| FY Dec 2023 | +47.0% |
| FY Dec 2022 | +21.8% |
| FY Dec 2021 | +57.5% |
| Jun 2026 | n/a |
| Mar 2026 | +14.3% |
| Dec 2025 | +13.9% |
| Sep 2025 | +53.5% |
| Jun 2025 | +63.2% |
| Mar 2025 | +37.8% |
| Dec 2024 | +41.1% |
| Sep 2024 | +57.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-5.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SIGA
| FY Dec 2025 | +11.3% |
| FY Dec 2024 | +33.4% |
| FY Dec 2023 | +44.7% |
| FY Dec 2022 | +23.9% |
| FY Dec 2021 | +55.1% |
| Jun 2026 | -5.9% |
| Mar 2026 | +11.1% |
| Dec 2025 | +11.3% |
| Sep 2025 | +47.5% |
| Jun 2025 | +52.6% |
| Mar 2025 | +29.1% |
| Dec 2024 | +33.4% |
| Sep 2024 | +69.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SIGA
| FY Dec 2025 | 19.71x |
| FY Dec 2024 | 7.33x |
| FY Dec 2023 | 5.89x |
| FY Dec 2022 | 16.00x |
| FY Dec 2021 | 8.36x |
| Jun 2026 | n/a |
| Mar 2026 | 19.81x |
| Dec 2025 | 19.71x |
| Sep 2025 | 8.97x |
| Jun 2025 | 5.77x |
| Mar 2025 | 8.18x |
| Dec 2024 | 7.33x |
| Sep 2024 | 5.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$188.4M
market value at close 2026-10-26 on 2026-07-24 shares, plus long-term 2019-09-30 (82 months older than the period end) plus current 2020-12-31 (66 months older than the period end), minus cash 2026-06-30
Enterprise value SIGA
| FY Dec 2025 | $361.5M |
| FY Dec 2024 | $352.7M |
| FY Dec 2023 | $326.9M |
| FY Dec 2022 | $517.6M |
| FY Dec 2021 | $533.1M |
| Jun 2026 | $222.4M |
| Mar 2026 | $316.6M |
| Dec 2025 | $361.5M |
| Sep 2025 | $562.2M |
| Jun 2025 | $362.2M |
| Mar 2025 | $308.1M |
| Dec 2024 | $352.7M |
| Sep 2024 | $461.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-9.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield SIGA
| FY Dec 2025 | +9.9% |
| FY Dec 2024 | +11.4% |
| FY Dec 2023 | +23.8% |
| FY Dec 2022 | +7.7% |
| FY Dec 2021 | +2.1% |
| Jun 2026 | -7.9% |
| Mar 2026 | +7.2% |
| Dec 2025 | +9.9% |
| Sep 2025 | +17.8% |
| Jun 2025 | +25.5% |
| Mar 2025 | +15.8% |
| Dec 2024 | +11.4% |
| Sep 2024 | +14.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SIGA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.06x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.33x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $94.6M | $138.7M | $139.9M | $110.8M |
| Operating income | $23.7M | $70.0M | $83.6M | $42.7M |
| Net income | $23.3M | $59.2M | $68.1M | $33.9M |
| EPS (diluted) | 0.32 | 0.82 | 0.95 | 0.46 |
| Operating cash flow | $43.5M | $48.8M | $94.8M | $41.6M |
| Cash | $155.0M | $155.4M | $150.1M | $98.8M |
| Buybacks | $0 | $0 | $11.1M | $13.0M |
| Dividends paid | $43.1M | $42.7M | $32.1M | $32.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
SIGA Stock Sonar score 5/7 axes
Find similar shapesCompareSIGA ranks highest on profitability (81st percentile) and institutional and government (68th), and lowest on growth (20th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
